News | June 10, 2007

Cardio BioSciences Licenses Mayo Clinic’s Cardiac Stem Cell Technology

June 11, 2007 — Cardio BioSciences and Mayo Clinic announced today that they have entered into a collaborative agreement related to the licensing of Mayo Clinic research, know-how and intellectual property in the field of cardiac commitment of stem cells, in a move that positions Cardio_ BioSciences as a global leader in the field of regenerative therapies for heart failure

The research, headed by Andre Terzic, MD, PhD and Atta Behfar, M.D., at Mayo Clinic, has focused on the guided commitment of adult as well as embryonic stem cells. The scope of the license covers heart failure of ischemic and non-ischemic origin.

“This opportunity positions Cardio BioSciences as a global leader in the field of regenerative therapies for heart failure,” said Christian Homsy, MD, CEO of Cardio_ BioSciences. “The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.”

“Over one million Americans suffer a new or recurrent heart attack each year. Despite the aggressive approaches we use to treat heart patients, no effective means are available to repair a damaged heart,” added Terzic. “Discoveries by the Mayo team open new therapeutic avenues exploiting the regenerative potential of stem cells guided toward cardiac lineage. We are excited about translating this novel methodology into repair strategies.”

For more information: www.cardio3bio.com and www.mayoclinic.com

Related Content

The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.

The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.

Feature | Stem Cell Therapies | May 11, 2021 | By Simon H. Stertzer, M.D.
Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections
Astronaut Jessica Meir “feeds” a set of the University of Washington’s engineered heart tissues (inside the green-topped case at center) riding aboard the International Space Station as part of a test of micro-gravity on heart health. Image courtesy of NASA. 

Astronaut Jessica Meir “feeds” a set of the University of Washington’s engineered heart tissues (inside the green-topped case at center) riding aboard the International Space Station as part of a test of micro-gravity on heart health. Image courtesy of NASA. 

Feature | Stem Cell Therapies | February 25, 2021 | By Andy Freeberg
The University of Washington (UW) in Seattle has developed engineered heart tissue that beats.
Renovacor Closes $11 Million Series A Financing for New Cardiovascular Gene Therapy
News | Stem Cell Therapies | August 22, 2019
August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion o
Placental Stem Cells Can Regenerate the Heart After Heart Attack
News | Stem Cell Therapies | May 20, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta...
ProxiCor Extracellular Matrix Reduces Complications, Readmissions Following Pericardial Reconstruction
News | Stem Cell Therapies | April 19, 2019
Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of...
FDA Releases Final Guidances on Regenerative Medicine Therapies
News | Stem Cell Therapies | March 04, 2019
The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding regenerative medicine...
Heart Muscle Cells Created From Stem Cells Beat in Sync
News | Stem Cell Therapies | February 01, 2019
A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts heal themselves – a...
FDA Clamps Down on Unapproved Stem Cell Therapies
News | Stem Cell Therapies | December 20, 2018
December 20, 2018 — The U.S.
Secant Introduces First Synthetic Regenerative Cardiovascular Graft for CABG
News | Stem Cell Therapies | January 17, 2018
Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance...
News | Stem Cell Therapies | October 24, 2017
October 24, 2017 — Roche and Ncardia have reached a broad licensing agreement whereby Roche and its affiliate compani